Modeling Highlights the Challenge of Achieving and Maintaining HCV Micro-Elimination Among People Who Inject Drugs

Clicks: 3
ID: 315986
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #151 of 214 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 214 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background People who inject drugs (PWID) are at high risk for acquiring and transmitting hepatitis C virus (HCV). Direct-acting antiviral (DAA) therapy leads to high cure rates. However, lack of protective immunity after cure and high reinfection rates in PWID necessitates access to multiple DAA treatments per PWID to reach the World Health Organization HCV elimination goal of 90% incidence reduction. A major public health challenge is determining the proportion of PWID to treat to reach the goal and the continued treatment levels required to maintain decreased incidence. Methods We used an agent-based model to study varying levels of DAA treatment among HCV-infected PWID from Chicago, IL and the effects of reducing DAA treatment after elimination is reached. The model uses individual temporal viral load profiles to determine transmission probabilities relative to the HCV RNA titers of receptive syringe-sharing PWID. Results Modeling predicts that insufficient DAA treatment can result in a continuous increase of HCV incidence over a 25-year period, with no significant decrease. Elimination can be achieved within 10 years with sufficient treatment levels. However, when DAA treatment is stopped, rates of new chronic HCV infections rapidly increase, returning to pre-elimination levels within 5 years. Annual treatment of ≥0.5% would maintain the elimination goal but identifying and treating small numbers of infected people annually in PWID populations, would be resource intensive. Conclusions The challenge to achieve and maintain the elimination goal underscores the importance of augmenting DAA treatment with intervention strategies such as syringe service programs and vaccines.
Reference Key
openalex_W7163698359 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Eric Tatara, Louis Shekhtman, Nicholson Collier, Scott J. Cotler, Mary Ellen Mackesy‐Amiti, Basmattee Boodram, Harel Dahari, Marian Major, Jonathan Ozik
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag297
URL
https://doi.org/10.1093/ofid/ofag297
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.